Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity through the Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) grant, aimed at facilitating time-sensitive ancillary studies related to ongoing clinical projects under the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This initiative allows applicants to explore new research questions not addressed in parent studies, utilizing existing resources and patient cohorts to enhance scientific understanding and potentially improve diagnostics and treatments for diseases within the NIAMS portfolio. Eligible applicants include higher education institutions, nonprofits, and government agencies, with a funding ceiling of $250,000 per year and a total request limit of $400,000 over two years. Applications are due by December 5, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.